when is tirzepatide off patent Looming GLP-1 drug expirations draw generics firms In weight loss battle, Novo

They are medical doctors with the authority to write prescriptions

clinical studies show that discontinuation typically results in weight regain

It gives Novo Nordisk an opportunity to remain competitive on efficacy while it continues developing next-generation therapies. Other drugs have already shown greater efficacy in prior studies, and the broader GLP-1 space is likely to see much more significant change as new molecules enter the market. Balazs called the higher dosage a major jump, noting that the incidences of stomach- and skin-related side effects at this higher dose are meaningful. CLICK HERE FOR MORE HEALTH STORIES This approval is for obesity management, not diabetes treatment, the expert emphasized

Trials show improvements in A1C, triglycerides, inflammatory markers, and joint pain

Here's a quick reference table that outlines the FDA-approved GLP-1 receptor agonists, including their brand names and approval dates

Because of this dual action, Mounjaro is often described as a dual incretin therapy